BioLattice Ophthalmics is a Philadelphia biotech developing engineered corneal tissue to replace human donor corneas. Its lead product, CorneaClear, is a synthetic, biocompatible, room-temperature-stable corneal implant intended to be implanted using the same procedure surgeons already use for donor tissue. The company targets corneal blindness, which it describes as affecting roughly 2 million new patients a year with only about 1 in 70 patients who need cornea tissue receiving it. It was co-founded by Amelia Zellander (Chief Scientific Officer) and Linda Alunkal (Chief Executive Officer), has an NSF SBIR Phase I grant, and went through SOSV's IndieBio program.